drugset / Trial / NCT03506399
A Study of Lanabecestat in Healthy Female Participants Taking Oral Contraceptive
RandomizedCrossoverOpen-labelBasic science
Summary
The study will evaluate the effect of oral contraceptive (birth control pill) on the blood level of lanabecestat when both are given together. Side effects will be monitored and documented. This study will last up to 27 days for each participant, not including screening. Screening is required within 42 days prior to first dose.
Timeline
- Start
- 2018-06
- Primary completion
- 2018-10
- Completion
- 2018-10
Outcome
Outcome not reported
Stopped: “Stopped for futility. Phase 3 studies not likely to meet primary endpoints.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lanabecestat | Small molecule | — | Oral |
| Subject | Levonorgestrel | Small molecule | — | Oral |
| Subject | ethinyl estradiol | Small molecule | — | Oral |
Indications
No indication recorded.